FDA Extends Review Period for Ruxolitinib Cream for Vitiligo
The sNDA submission included data from the phase 3 TRuE-V clinical trial program.
Vitiligo
Ruxolitinib Cream Gets Priority Review for Vitiligo Treatment
The application is supported by data from the phase 3 TRuE-V clinical trial program.
MPR Weekly Dose Podcast 79
This week we have news of changes to the storage of the Pfizer-BioNTech vaccine; A gene therapy gets Fast Track status by the FDA; Vitiligo cream shows promise in clinical trials; And outcomes in atherosclerotic cardiovascular disease are compared for different aspirin dosages.
Repigmentation Observed With Ruxolitinib Cream in Vitiligo Trials
Results from both studies demonstrated that ruxolitinib met the primary endpoint with a greater proportion of patients achieving F-VASI75 at week 24.
